Navigation Links
VirtualScopics Reports Record Third Quarter 2008 Revenue and Gross Profit
Date:11/4/2008

n place nearly a year ago has positioned us very well from a competitive, operational and financial perspective. We are looking forward to a solid close to the year."

Jeff Markin and Chief Business and Financial Officer, Molly Henderson will provide a business update and discuss these results during the conference call on Wednesday, November 5, 2008 at 11:00 a.m. EST. Interested participants should call 877-407-0778 when calling within the United States or 201-689-8565 when calling internationally. There will be a playback available until December 5, 2008. To listen to the playback, please call 877-660-6853 when calling within the United States or 201-612-7415 when calling internationally. For the replay, please use account number: 286, conference ID number: 301146.

About VirtualScopics, Inc.

VirtualScopics, Inc. is a leading provider of imaging solutions to accelerate drug and medical device development. VirtualScopics has developed a robust software platform for analysis and modeling of both structural and functional medical images. In combination with VirtualScopics' industry-leading experience and expertise in advanced imaging biomarker measurement, this platform provides a uniquely clear window into the biological activity of drugs and devices in clinical trial patients, allowing sponsors to make better decisions faster. For more information about VirtualScopics, visit http://www.virtualscopics.com.

Forward-Looking Statements

The statements contained in this press release that are not purely historical are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended, and are intended to be covered by the safe harbors created thereby. These forward-looking statements include, but are not limited to, statements regarding the expected benefits of the Company's inves
'/>"/>

SOURCE VirtualScopics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. VirtualScopics to Present at Two Upcoming Investor Conferences
2. VirtualScopics Schedules Third Quarter 2008 Earnings Announcement
3. VirtualScopics Reports Second Quarter 2008 Results
4. VirtualScopics Receives NASDAQ Delisting Notice; Company Files Appeal to Stay Delisting
5. VirtualScopics Backlog Exceeds a Record $20 Million
6. VirtualScopics Announces $4.35 Million Private Placement
7. Vion Reports 2008 Third Quarter and Nine-Month Results
8. AMICAS Reports Financial Results for the Third Quarter Ended September 30, 2008
9. Neovasc Reports Development Progress, Streamlined Operations and Issuance of Options
10. NxStage Reports Third Quarter 2008 Financial Results
11. Study reports Double Balloon Endoscopy useful for diagnosis and treatment of obscure GI bleeding

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/8/2009)...UCW Academy of Health holds open house at Victoria...ocus) November 8, 2009 -- UCW Academy of Health in...Columbia’s health care industry to attend th...25, 2009. , ,UCW Academy of Health, which offers ...and social services, designs its programs to meet ...
(Date:11/8/2009)...New book called "Preventing and Healing AIDS ...raldo shows that AIDS is a result of multiple, rep...ed immune system stressor agents, which can be eit...l, emotional. , Oakland,...; 8, 2009, cell biologists, physicians, chemists a...
(Date:11/8/2009)...PRNewswire-USNewswire/ -- Today, the House of Repr...kemper, Smith, Ellsworth and Lipinski amendment to.... 3962). The amendment maintains the current polic...or benefits packages that include abortion. It cla...fordability credits and those who do not, can with...
(Date:11/8/2009)...sage of H.R. 3961 to Secure the Stability of Medic... -- Statement Attributable to: J. James Rohack, M.... (Logo: http://www.newscom.com/cgi-bin/prnh/2008...of the House health reform bill, which will help i...ns and calls for swift passage of H.R. 3961 to sec...
(Date:11/8/2009)...ov. 8 March of Dimes ho...eon to recognize prominent individuals who are cel...ole models for March of Dimes commitment to improv...imes November Prematurity Awareness Month campaign...n the fight for preemies! ,, (Photo: http://w...
Breaking Medicine News(10 mins):Health News:College Invites Public to Explore Career Options in Health Care 2Health News:Revolutionary New Views on AIDS Highlight the Rethinking AIDS 2009 Congress; Emotional Issues can be a Significant Contributing Factor 2Health News:Revolutionary New Views on AIDS Highlight the Rethinking AIDS 2009 Congress; Emotional Issues can be a Significant Contributing Factor 3Health News:Family Research Council Praises Passage of Pro-life Amendment to Health Care Bill 2Health News:AMA Hails House Passage of Health Reform Bill (H.R. 3962) 2Health News:Hollywood Stars Joined in a Celebration of Babies 2Health News:Hollywood Stars Joined in a Celebration of Babies 3
...) --,HearAtLast Holdings, Inc. is proud to announc...art Canada (NYSE: WMT ) to open its 16th hearing-...located at 255 Silver Linden,Dr. in Richmond Hill,... its option under a master licensing agreement wit...
...standard being adopted worldwide by, pharmaceutica... confirming digital iden...ms,(Nasdaq: ALDN ), an information security leade... hardware product,to be certified under the recent...
...Diverse Expertise, MIAMI, Dec. 9 Novis Pharmaceu...oducts to healthcare providers, is pleased,to anno...e President of,Human Resources. Ms. Lopez was most...ating from Florida International,University (FIU)....
...eruse of colorectal cancer screening procedures am...n the January 15, 2008 issue of CANCER, a peer-rev... that only 25 percent of Medicare patients receive... States. The American Cancer Society estimates tha...
... believe or disbelieve a statement is a powerful f...t the basis of these states in the brain is not ye...lief and uncertainty activate distinct regions of ... the Annals of Neurology ( http://www.interscience...
...sone improved pre, - and post-stem cell transplan... dexamethasone -, ATLANTA, Dec...M ) reported the presentation of results from an i...nd,dexamethasone (VcTD) to thalidomide and dexamet...
Other Medicine News:Health News:HearAtLast Continues Expansion Announcing Opening of New Clinic Location in Sam's Club in Richmond Hill, Ontario 2Health News:HearAtLast Continues Expansion Announcing Opening of New Clinic Location in Sam's Club in Richmond Hill, Ontario 3Health News:HearAtLast Continues Expansion Announcing Opening of New Clinic Location in Sam's Club in Richmond Hill, Ontario 4Health News:Aladdin eToken First Strong Authentication Device to Achieve Certification from the SAFE-BioPharma Association 2Health News:Aladdin eToken First Strong Authentication Device to Achieve Certification from the SAFE-BioPharma Association 3Health News:Aladdin eToken First Strong Authentication Device to Achieve Certification from the SAFE-BioPharma Association 4Health News:Novis Pharmaceuticals Hires Lisa Lopez 2Health News:Many Medicare beneficiaries not receiving colorectal cancer screening 2Health News:Belief, disbelief and uncertainty activate distinct brain regions 2Health News:Phase III Trial of VELCADE(R) (Bortezomib) for Injection Showed Dramatic Fourfold Increase in Complete Remission Rates When Combined With the Most Commonly Used U.S. Regimen in Front-Line Multiple Myeloma 2Health News:Phase III Trial of VELCADE(R) (Bortezomib) for Injection Showed Dramatic Fourfold Increase in Complete Remission Rates When Combined With the Most Commonly Used U.S. Regimen in Front-Line Multiple Myeloma 3Health News:Phase III Trial of VELCADE(R) (Bortezomib) for Injection Showed Dramatic Fourfold Increase in Complete Remission Rates When Combined With the Most Commonly Used U.S. Regimen in Front-Line Multiple Myeloma 4Health News:Phase III Trial of VELCADE(R) (Bortezomib) for Injection Showed Dramatic Fourfold Increase in Complete Remission Rates When Combined With the Most Commonly Used U.S. Regimen in Front-Line Multiple Myeloma 5Health News:Phase III Trial of VELCADE(R) (Bortezomib) for Injection Showed Dramatic Fourfold Increase in Complete Remission Rates When Combined With the Most Commonly Used U.S. Regimen in Front-Line Multiple Myeloma 6
(Date:11/6/2009)...M, N.C., Nov. 6 Oxygen B...day announced that a previously approved reverse s...tart of trading on Monday, Nov. 9, 2009 on a 1-for...Inc. shares will trade under the new symbol OXBT. ...P 20 9, when the split becomes effective. ,, "T...
(Date:11/6/2009)...STOWN, N.J., Nov. 6 Wats...specialty pharmaceutical company, announced today ...cutive officer, will provide an overview and updat...8th Annual Healthcare Conference on Wednesday, Nov...,, This presentation will be webcast live and c...
(Date:11/6/2009)...ESTON, S.C., Nov. 6 T...g in South Carolina and Georgia throughout the wee...elp uninsured and financially-struggling patients ...iption medicines for free or nearly free. With the...nt, the Partnership for Prescription Assistance (P...
Breaking Medicine Technology:Oxygen Biotherapeutics, Inc. Announces 1:15 Reverse Stock Split to Take Effect Nov. 9, 2009 2Oxygen Biotherapeutics, Inc. Announces 1:15 Reverse Stock Split to Take Effect Nov. 9, 2009 3Partnership for Prescription Assistance Prepared to Help Southern Workers Hurt by Recession 2Partnership for Prescription Assistance Prepared to Help Southern Workers Hurt by Recession 3Study Shows Otamixaban Substantially Reduced Complications of Invasive Management of Acute Coronary Syndromes 4918 1Study Shows Otamixaban Substantially Reduced Complications of Invasive Management of Acute Coronary Syndromes 4918 2Study Shows Otamixaban Substantially Reduced Complications of Invasive Management of Acute Coronary Syndromes 4918 3Study Shows Otamixaban Substantially Reduced Complications of Invasive Management of Acute Coronary Syndromes 4918 4New Large Scale Global Study Provides Additional Information About an Intensified Dose Regimen of PLAVIX 28R 29 in Acute Coronary Syndrome Patients U 4917 1New Large Scale Global Study Provides Additional Information About an Intensified Dose Regimen of PLAVIX 28R 29 in Acute Coronary Syndrome Patients U 4917 2New Large Scale Global Study Provides Additional Information About an Intensified Dose Regimen of PLAVIX 28R 29 in Acute Coronary Syndrome Patients U 4917 3New Large Scale Global Study Provides Additional Information About an Intensified Dose Regimen of PLAVIX 28R 29 in Acute Coronary Syndrome Patients U 4917 4New Large Scale Global Study Provides Additional Information About an Intensified Dose Regimen of PLAVIX 28R 29 in Acute Coronary Syndrome Patients U 4917 5Get Ready for Ragweed 55647 1Get Ready for Ragweed 55647 2
... Italy, April 26 Schering-Plough Corporation,(NYS...ed interim analysis of,an ongoing Phase II study o... protease inhibitor, in 595 treatment-naive patien... were presented at the 43rd Annual,Meeting of the ...ASL). The,ongoing study evaluates boceprevir in 28...
...Large Study Comparing Leading Hepatitis C Therapie...ide Clinical Practice, MILAN, Italy, April 26 Fi...andomized, clinical study comparing the,leading th...day at the 43rd,Annual Meeting of the European Ass...ing important insights that may help guide clinica...
Other Medicine Technology:Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment-Naive Hepatitis C Patients Presented At EASL 2Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment-Naive Hepatitis C Patients Presented At EASL 3Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment-Naive Hepatitis C Patients Presented At EASL 4Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment-Naive Hepatitis C Patients Presented At EASL 5Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment-Naive Hepatitis C Patients Presented At EASL 6Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment-Naive Hepatitis C Patients Presented At EASL 7Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment-Naive Hepatitis C Patients Presented At EASL 8Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment-Naive Hepatitis C Patients Presented At EASL 9Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL) 2Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL) 3Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL) 4Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL) 5Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL) 6Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL) 7Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL) 8Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL) 9Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL) 10
...o-Surgery provides clip appliers in 10mm and 5mm s...iers provide precise clip placement., ,The ALLPOR...e preloaded, single-trigger instruments are design... a 5mm trocar, through a 5mm reducer cap in a larg...
...P-HS assay utilizes turbidimetric immunoassay meth...uring over the range of 0.2-28.0 mg/dL. This assay...to most clinical chemistry analyzers. The Wako CRP...ecision, linearity, correlation, and sensitivity. ...
LabDAQ3 Laboratory Information System
...e for laboratories to work more efficiently has ne...e solutions. With the COBAS INTEGRA® 400 plus,...ies, robotic handling of reaction cuvettes and imp...broad menu and ease-of-use required for true workl...
Medicine Products: